Among different strategies used to activate the immune system against tumor cells, the immune-checkpoint inhibitors, such as anti-programmed death receptor-1/programmed cell death receptor-ligand-1 (anti-PD-1/PD-L1) and anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) monoclonal antibodies are widely recognized [3,4]. This evidence concerns the gene CTLA4 and neoplasm.